OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer
Chaping Cheng, Jinming Wang, Penghui Xu, et al.
Nature Cancer (2022) Vol. 3, Iss. 5, pp. 565-580
Closed Access | Times Cited: 42
Chaping Cheng, Jinming Wang, Penghui Xu, et al.
Nature Cancer (2022) Vol. 3, Iss. 5, pp. 565-580
Closed Access | Times Cited: 42
Showing 1-25 of 42 citing articles:
Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome
Jing Sun, Jianhui Zhao, Fangyuan Jiang, et al.
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 92
Jing Sun, Jianhui Zhao, Fangyuan Jiang, et al.
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 92
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation
Milad Ashrafizadeh, Wei Zhang, Yu Tian, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 229-260
Closed Access | Times Cited: 17
Milad Ashrafizadeh, Wei Zhang, Yu Tian, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 1, pp. 229-260
Closed Access | Times Cited: 17
OTUD4 promotes the progression of glioblastoma by deubiquitinating CDK1 and activating MAPK signaling pathway
Mingxin Ci, Gaichao Zhao, Chongyang Li, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 9
Mingxin Ci, Gaichao Zhao, Chongyang Li, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 3
Open Access | Times Cited: 9
Integrin‐Targeted, Activatable Nanophototherapeutics for Immune Modulation: Enhancing Photoimmunotherapy Efficacy in Prostate Cancer Through Macrophage Reprogramming
Cheng Zhang, Xiaolan Yin, Lei Hao, et al.
Aggregate (2025)
Open Access | Times Cited: 1
Cheng Zhang, Xiaolan Yin, Lei Hao, et al.
Aggregate (2025)
Open Access | Times Cited: 1
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway
Jinming Wang, Penghui Xu, Zhongzhong Ji, et al.
Nature Cancer (2025)
Closed Access | Times Cited: 1
Jinming Wang, Penghui Xu, Zhongzhong Ji, et al.
Nature Cancer (2025)
Closed Access | Times Cited: 1
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation
Fan Luo, Han Li, Wenjuan Ma, et al.
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 1, pp. 60-79
Open Access | Times Cited: 22
Fan Luo, Han Li, Wenjuan Ma, et al.
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 1, pp. 60-79
Open Access | Times Cited: 22
Label-free biosensing with singular-phase-enhanced lateral position shift based on atomically thin plasmonic nanomaterials
Shaodi Zhu, Rodolphe Jaffiol, Aurelian Crunteanu, et al.
Light Science & Applications (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Shaodi Zhu, Rodolphe Jaffiol, Aurelian Crunteanu, et al.
Light Science & Applications (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers
Baijun Dong, Jun‐Yu Xu, Yuqi Huang, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1427-1447
Closed Access | Times Cited: 5
Baijun Dong, Jun‐Yu Xu, Yuqi Huang, et al.
Nature Cancer (2024) Vol. 5, Iss. 9, pp. 1427-1447
Closed Access | Times Cited: 5
GREM1 is a potential biomarker for the progression and prognosis of bladder cancer
Pengcheng Jiang, Li‐zhe Xu, Jinzhuo Ning, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Pengcheng Jiang, Li‐zhe Xu, Jinzhuo Ning, et al.
World Journal of Surgical Oncology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Role of gremlin-1 in the pathophysiology of the adipose tissues
Elisabetta Grillo, Cosetta Ravelli, Georgia Colleluori, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 69, pp. 51-60
Open Access | Times Cited: 17
Elisabetta Grillo, Cosetta Ravelli, Georgia Colleluori, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 69, pp. 51-60
Open Access | Times Cited: 17
A comprehensive prognostic and immunological implications of Gremlin 1 in lung adenocarcinoma
Hongyan Li, Yang Zhou, Junze Xiao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Hongyan Li, Yang Zhou, Junze Xiao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Ex.50.T aptamer impairs tumor–stroma cross-talk in breast cancer by targeting gremlin-1
Cristina Quintavalle, F. Ingenito, Giuseppina Roscigno, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Cristina Quintavalle, F. Ingenito, Giuseppina Roscigno, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Eloise Clarkson, Annabelle Lewis
The Journal of Pathology (2025)
Open Access
New insights into Gremlin-1: A tumour microenvironment landscape re-engineer and potential therapeutic target
Cheng‐Peng Sun, Zijun Ding, B. Li, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2025), pp. 119962-119962
Closed Access
Cheng‐Peng Sun, Zijun Ding, B. Li, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2025), pp. 119962-119962
Closed Access
KMT2C deficiency drives transdifferentiation of double-negative prostate cancer and confer resistance to AR-targeted therapy
Jiacheng Guo, Li Ni, Qiuli Liu, et al.
Cancer Cell (2025)
Closed Access
Jiacheng Guo, Li Ni, Qiuli Liu, et al.
Cancer Cell (2025)
Closed Access
Angiogenic and Fibrogenic Dual-effect of Gremlin1 on Proliferative Diabetic Retinopathy
Xinjing Wu, Bing Qin, Ruiwen Cheng, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 3, pp. 897-915
Open Access | Times Cited: 3
Xinjing Wu, Bing Qin, Ruiwen Cheng, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 3, pp. 897-915
Open Access | Times Cited: 3
GREM1 signaling in cancer: tumor promotor and suppressor?
Zhichun Gao, Julia M. Houthuijzen, Peter ten Dijke, et al.
Journal of Cell Communication and Signaling (2023) Vol. 17, Iss. 4, pp. 1517-1526
Open Access | Times Cited: 8
Zhichun Gao, Julia M. Houthuijzen, Peter ten Dijke, et al.
Journal of Cell Communication and Signaling (2023) Vol. 17, Iss. 4, pp. 1517-1526
Open Access | Times Cited: 8
Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer
Gareth Davies, Neesha Dedi, Paul S. Jones, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Gareth Davies, Neesha Dedi, Paul S. Jones, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 8
GREMLIN1 disrupts intestinal epithelial-mesenchymal crosstalk to induce a wnt-dependent ectopic stem cell niche via stromal remodelling
Eoghan J. Mulholland, HL. Belnoue-Davis, Gabriel N. Valbuena, et al.
(2024)
Closed Access | Times Cited: 2
Eoghan J. Mulholland, HL. Belnoue-Davis, Gabriel N. Valbuena, et al.
(2024)
Closed Access | Times Cited: 2
Comprehensive data mining reveals RTK/RAS signaling pathway as a promoter of prostate cancer lineage plasticity through transcription factors and CNV
Guanyun Wei, Xu Zhang, Siyuan Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Guanyun Wei, Xu Zhang, Siyuan Liu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 2
Treatment-induced stemness and lineage plasticity in driving prostate cancer therapy resistance
Anmbreen Jamroze, Xiaozhuo Liu, Dean G. Tang
(2024), pp. 1-35
Open Access | Times Cited: 2
Anmbreen Jamroze, Xiaozhuo Liu, Dean G. Tang
(2024), pp. 1-35
Open Access | Times Cited: 2
Gremlin1: a BMP antagonist with therapeutic potential in Oncology
Jin Zhao, Yanshuo Cao
Investigational New Drugs (2024)
Closed Access | Times Cited: 2
Jin Zhao, Yanshuo Cao
Investigational New Drugs (2024)
Closed Access | Times Cited: 2
Emerging proteins involved in castration‑resistant prostate cancer via the AR‑dependent and AR‑independent pathways (Review)
Kangle Feng, Chunhua Liu, Weixi Wang, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 5
Open Access | Times Cited: 4
Kangle Feng, Chunhua Liu, Weixi Wang, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 5
Open Access | Times Cited: 4
YAP1 Regulates the YAP1/AR/PSA Axis through Autophagy in Castration-Resistant Prostate Cancer and Mediates T-Cell Immune and Inflammatory Cytokine Infiltration
Youzhi Wang, Ning Wu, Junbo Li, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 661-661
Open Access | Times Cited: 1
Youzhi Wang, Ning Wu, Junbo Li, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 661-661
Open Access | Times Cited: 1
